


09/771,536



1646 Set

12273-3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: LANGRIDGE, William H.R. et al. Serial No.: 09/771,536 Filed: January 29, 2001	Group Art Unit: 1646 RECEIVED JAN 2 2 2002 Examining Attorney: to be assigned TECH CENTER 1600/2900
For: Transgenic Plant-Based Vaccines) Pasadena, California
TRANSMITTAL LETTER	
United States Patent and Trademark Office P.O. Box 2327 Arlington, VA 22202	
Sir:	
In response to the Notice to Co	mply with Requirements for Patent Applications
Containing Nucleotide Sequence and/or Amin	o Acid Sequence Disclosures dated December
18, 2001, enclosed are the following:	
1. Statement in Accordance with 37 CFR 1.821(c) and (e);	
2. Paper copy of Sequence Lis	ting;
Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202,	United States Postal Service as first class in an envelope addressed to: U.S., on <u>January 11, 2002</u>
Signature ELAINE PORTER	

09/771,536

3. Computer readable form of the Sequence Listing; and

4. A copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures.

No fee is believed due with this Communication. However, the Commissioner is hereby authorized to charge payment of any fees associated with this Communication to Deposit Account No. 19-2090.

Respectfully submitted,

SHELDON & MAK a Professional Corporation

Date: January 11, 2002

David A. Farah, M.D.

Reg. No. 38,134

Sheldon & Mak 225 South Lake Avenue 9th Floor Pasadena, CA 91101 626/796-4000



COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 2023I
www.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/771,536

01/29/2001

William H.R. Langridge

12273-3

CONFIRMATION NO. 9620 FORMALITIES LETTER

OC000000007205608

Sheldon & Mak c/o David A. Farah, M.D. 9th Floor 225 South Lake Avenue Pasadena. CA 91101

Date Mailed: 12/18/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of
the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as
indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a
substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content
of the sequence listing information recorded in computer readable form is identical to the written (on paper
or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR
1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice <u>MUST</u> be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY